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Al tract. Recently, we demonstrated that radiolabelled 
ini ieukin-la (IL-1) specifically accumulates in focal 
ini ction in mice through interaction with its receptor. 
Ui ortunately, systemic side-effects of IL-1 limit its 
cli cal application. We investigated whether this prob- 
lei could be circumvented by using the interleukin-1 re- 
ce or antagonist (IL-lra), an equally sized protein that 
bii s to the same receptors as IL-1 without induction of 
bi< ogical effects. Biodistribution of 125I-IL-1 and 125I- 
IL ra was determined in Swiss mice with Stciphylococ- 
cu aureus-induced abscesses in the left calf muscle at 4,
12 24 and 48 h after injection of either 0.4 MBq ,25I-IL- 
I ( 0.4 MBq ,25I-IL-lra. In vitro, the proteins displayed 
sin lar binding characteristics. High-performance liquid 
chi matographic analysis revealed a tendency for IL-lra 
to ssociate with serum proteins. Both proteins rapidly 
cle red from most organs. However, the abscess uptake 
of :5I-IL-1 ra was significantly lower than that of l25I- 
IL at all time points (48 h p.i.: 0.06±0.01%ID/g vs
0.6 ±0.04%ID/g; P<0.02). The abscess-to-contralateral 
nui cle ratios did not exceed 15.5±2.9 for 125I-IL-1 ra, 
wh e the ratios for ,25I-IL-1 reached 46.9±5.7 at 48 h 
p.i Despite similar in vitro receptor binding, the abscess 
upt ke of IL-lra was much lower than that of IL-1. The 
int action of IL-lra with serum proteins in vivo may re­
duce its availability for receptor binding in the infection. 
All ough on theoretical grounds IL-lra is very interest­
ing these characteristics will prevent its development as 
a i nically useful radiopharmaceutical to image infec­
tion.
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Introduction
The rather lengthy time required for infection localiza­
tion with conventional nuclear medicine techniques [1, 
2 ] has stimulated the search for new agents with better 
imaging properties. Small receptor binding peptides 
seem to be attractive candidates. Our previous study 
showed fast background clearance and good accumula­
tion of radiolabelled interleukin-1 (IL-1) - a 17-kDa cy­
tokine - in the infectious focus [3]. Extremely high ab- 
scess-to-background ratios were obtained and specific 
retention at the site of the infection was shown to be due 
to receptor binding.
Unfortunately, systemic side-effects of IL-1, such as 
fever and hypotension, hamper its clinical application 
[4]. These side-effects can occur at doses as low as
10 ng/kg. For these reasons, the potential of the naturally 
occurring IL-1 receptor antagonist (IL-lra) was studied. 
This equally sized molecule is structurally related to IL-
1 and binds to the IL-1 receptor with similar high affini­
ty, but does not initiate signal transduction, thus prevent­
ing any biological response [5]. Human studies have 
shown that patients injected with doses up to 10 mg/kg 
do not show any clinical signs and symptoms or changes 
in laboratory parameters [6 ]. Radiolabelled IL-lra there­
fore may be a potentially suitable imaging agent that can 
be applied clinically. In this study the in vitro and in vi­
vo behaviour of radioiodinated IL-lra was compared 
with that of IL-1.
Materials and methods
Radiolabelling of IL-1 and IL-lra
Human recombinant IL-1 a  (IL-1) and human recombinant IL-lra 
were kindly provided by Dr. P.T. Lomedico (Hoffman-La Roche, 
Nutley, N.J.) and Dr. R.C. Thompson (Synergen, Boulder, Colo.), 
respectively. IL-1 and IL-lra were radiolabelled according to the 
Bolton-Hunter method [7]. Briefly, 40 jig Bolton-Hunter reagent 
(Pierce, Rockford, 111.) was radiolabelled with 55 MBq iodine-125
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by incubating it with 5 |ig /V-chlorosuccinimide for 10 min at 
room temperature in methanol. The reaction was terminated by 
adding 5 (Llg Na->S-»05 to the reaction mixture. The methanol was 
evaporated with a gentle stream of N2. Subsequently, 10 jig IL-1 
or IL-lra in 2 j_il 1.0 M bicarbonate buffer, pH 8.2, was added and 
incubated for 15 min on ice.
Following the labelling reaction, the reaction mixture was ap­
plied to a Sephadex G-75 (Pharmacia, Uppsala, Sweden) column 
(0.7x50 cm; Biorad, Hercules, Calif.) and eluted with 0.025% gel­
atine in Tris-HCl buffer 1 mM EDTA pH 7.4 to separate labelled 
proteins from free l25I. The void fractions were pooled and steril­
ized through a 0.2-j.tm filter (Millipore. Milford, Mass.). The ra­
diochemical purity of the radiopharmaceuticals was determined as 
described [3].
Radiolabelled IL-1 and IL-lra preparations were analysed by 
high-performance liquid chromatography (HPLC) before and after 
incubation in mouse serum for 4 h at 37°C in order to test the sta­
bility of the radiolabelled proteins. A Shodex protein KW-802.5 
packed column with an M W  range of 100-50 000 (8x300 mm; 
Millipore, Milford, Mass.) was used. Tris-HCl buffer with 0.025% 
gelatine and 1 mM EDTA, pH 7.4, was used as the elution buffer. 
The flow rate was 0.5 ml/min.
Receptor binding assays
The murine cell line EL-4-6.1 [8], a kind gift of Dr. H.R. Mac­
Donald (Ludwig Institute for Cancer Research Epalinges, Swit­
zerland), was cultured at 37°C in a humidified atmosphere of 
aiiVC02 (95:5) in RPMI 1640 medium (GIBCO, Gaithersburg, 
Md.) containing 10% foetal calf serum. The EL-4 binding assays 
and Scatchard analyses were performed as described previously
[3].
Competitive binding assay. Live EL-4-6.1 cells were incubated 
with 2x10' 10 M l25I-IL-l or l25I-IL-lra and respectively serially 
diluted unlabelled IL-lra or IL-1 ( 10~l3-10~6 M). After an incuba­
tion period of 4 h at 4°C, cell-bound radioactivity was separated 
from unbound 125I-IL-1 by centrifugation (5 min, 2000 g) and 
measured in the gamma counter.
Bio distribution experiments
Staphylococcus aureus abscesses were induced in the left calf 
muscles of ether-anaesthetized Swiss mice (20-30 g) as described 
previously [3J. Twenty-four hours after the inoculation of S. au­
reus in the muscle, when swelling of the muscle was apparent, ei­
ther 0.4 MBq 125I-IL-1 or 0.4 MBq 125I-IL-1 ra was injected in the 
tail vein. Urine samples were analysed by HPLC 4 h after injec­
tion. Groups of five mice were killed under ether anaesthesia by 
cervical dislocation at 4, 12, 24 and 48 h after injection of the ra­
diopharmaceuticals. Several organs were dissected, weighed and 
counted in the gamma counter. The measured activity was ex­
pressed as a percentage of injected dose per gram tissue (%ID/g).
Analogously, to study the effect of the biological activity of 
IL-1 on the receptor binding of l25I-IL-1 ra in the infectious focus,
S. aureus-infected mice were injected with a mixture of 0.4 MBq 
125I-IL-1 ra and 150 ng unlabelled IL-1. The amount of IL-1 was 
chosen such that biological effects, including a wide range of in­
flammatory and immunological changes, could be induced [9J 
without receptor saturation.
StatisticaI analysis
All values are expressed as mean ± standard error of the mean 
(s.e.m.). Statistical analysis was performed using the one-way 
analysis of variance (ANOVA).
Results
Radiolabelling and characterization 
of the radiolabelled proteins
The labelling efficiencies for both 125I-IL-1 and l25I-IL- 
lra were in the range of 20%-30%. The specific activi­
ties of l25I-IL-l and ,25I-IL-lra were 0.3-0.7 MBq/jag. 
The radiochemical purity of all radiopharmaceuticals 
was higher than 95% after gel filtration. The preparation 
of radiolabelled IL-1 remained stable in mouse serum, as 
shown by the results of HPLC analyses before and 4 h 
after incubation of l25I-IL-l in mouse serum at 37°C 
(Fig. 1 A,C). After 4 h, most of the radioiodine was still 
IL-1 bound. In contrast, the HPLC profiles of 125I-IL-1 ra 
demonstrated a shift of radioactivity from 17 kDa to a 
higher molecular weight compound (>60 kDa) after 4 h 
incubation in mouse serum (Fig. 1B,D). To investigate 
whether this shift could be attributed to either aggrega­
tion of IL-lra or association of 125I-IL-1 ra with serum 
proteins, 125I-IL-lra was incubated in phosphate-buf­
fered saline (PBS) as well. Samples were analysed alter 
30 min and 4 h incubation of the protein in PBS oi 
mouse serum at 37°C. The shift to high moleculai 
weight products could already be observed after 30 mir 
in mouse serum. After 4 h, most of the radioactivity wa: 
found in the high molecular weight range. However, th( 
shift to the high molecular weight compounds was no 
found when I25I-IL-lra was incubated in PBS (data no 
shown).
ELUTION VOLUME (ML) ELUTION VOLUME (ML)
ELUTION VOLUME (ML) ELUTION VOLUME (ML)
Fig. 1. HPLC profiles of the l25I-IL-l preparation and the l2-sI-I 
Ira preparation before injection (A and B, respectively) and af 
4 h incubation in mouse serum at 37°C (C and D, respectivel 
The amount of radioactivity collected in each fraction is plotted 
a percentage of the total amount added to the HPLC column. I 
elution volume per fraction was 0.5 ml
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2. The competitive binding assay. The binding of 125I-IL-1 to 
receptors on EL-4-6.1 cells was inhibited by increasing 
»lints of unlabelled IL-lra. Analogously, the binding of 125I-IL- 
vvas inhibited by increasing amounts of unlabelled IL-1
The receptor binding fraction of both 125I-IL-1 and 
-IL-lra for conditions representing infinite cell re- 
tor excess was always between 60% and 75%. The 
-specific binding was less than 5%. Scatchard analy- 
revealed that ,25I-IL-1 and 125I-IL-1 ra bind to the IL- 
ceptor on EL-4 cells with almost equal affinities, re- 
sp Jtively 5.4xl0-11 and 4.7x10_M mol/1. Furthermore, 
as hown by the results of the competitive binding assay 
iF :. 2), the binding of ,25I-IL-1 to its receptor on the 
El 4 cells could be completely inhibited by an excess of 
un ibelled IL-lra with an IC50 value of 3.5xl0~10 mol/1. 
T1 inhibition of 125I-IL-1 ra by unlabelled IL-1 was 
eq ally efficient, with an IC50 value of 4.6x10_,° mol/1.
Bioclistribation experimen ts
Both radiolabelled IL-1 and IL-lra rapidly cleared from 
the blood and most other organs (Table 1). After 4 h p.i., 
only 0.52±0.04%ID/g and 0.98±0.07%ID/g for ,25I-IL-1 
and l25I-IL-lra, respectively, was retained in circulation. 
Most of each of the radiolabelled proteins was excreted 
via the kidneys during the first hours after injection. 
Both proteins were mainly excreted in the urine as low 
molecular weight metabolites: 2.5-3.5 kDa as deter­
mined by the Rf values obtained from the HPLC profiles 
(data not shown).
Despite its rapid blood clearance, ,25I-IL-1 was re­
tained in the abscess at >0.6%ID/g from 4 h p.i. on­
wards. Although 125I-IL-1 ra cleared even somewhat 
slower from circulation, the retention in the abscess was 
10 times lower (0.06%ID/g at 48 h p.i.) (Fig. 3). At all 
time points, the abscess uptake of ,25I-IL-lra was signif­
icantly lower than that of 125I-IL-1 (/D<0.02).
Retention in the abscess of 125I-IL-1, and to a lesser 
extent of 125I-IL-lra, was demonstrated by increasing 
abscess-to-contralateral muscle ratios of both agents in 
the time course of the study (Fig. 4). The abscess-to- 
contralateral muscle ratios of 125I-IL-1 increased from 
3.8±0.5 at 4 h p.i. to 46.9±5.7 at 48 h p.i. The ratios of 
125I-IL-1 ra increased to a significantly lower value of
15.5±2.9 at 48 h p.i. (P<0.005).
Table 2 summarizes the biodistribution data of S. ciu- 
reus-infected mice i.v. injected with a mixture of ,25I-IL- 
lra and unlabelled IL-1. The biodistribution data of l25I- 
IL-lra in these mice are highly similar to the data shown 
in Table 1, when no unlabelled IL-1 was adminstered to 
the mice. The abscess uptake did not change significant­
ly as a result of the co-injection of a small amount of un­
labelled IL-1 during the time span of the study.
Tal e 1. Biodistribution of 125I-IL-1 and 
:i  L-lra (%dose/g, mean values ±s.e.m.) Organ Radio­
pharmaceutical
4 h p.i. 12 h p.i. 24 h p.i. 48 h p.i.
Blood I25I-IL-1 0.52±0.04 0.09±0.02 0.02±0.002 0.01 ±0.002
125I-IL-1 ra 0.98±0.07 0 .16±0.02 0.03±0.004 0.02±0.0005
Abscess 125I-IL-1 0.98±0.05 0.83±0.07 0.72±0.06 0.60±0.04
125I-IL-1 ra 0.81±0.03 0.23±0.01 0.11±0.01 0.06±0.01
Muscle 125I-IL-1 0.27±0.02 0.08±0.004 0.03±0.004 0.01 ±0.002
125I-IL-1 ra 0.21 ±0.02 0.06±0.01 0.01 ±0.002 0.005±0.002
Thymus 125I-IL-1 0.73±0.11 0.37±0.01 0.22±0.01 0.08±0.01
125I-IL-1 ra 0.52±0.06 0 .13±0.006 0.03±0.002 0.01 ±0.005
Lung ,25I-IL-1 1.72±0.23 0.27±0.02 0.09±0.01 0.02±0.004
125I-IL-1 ra 1.08±0.03 0.28±0.006 0.07±0.004 0.03±0.002
Spleen l25I-IL-l 2.42±0.28 0.63±0.05 0.24±0.03 0.11 ±0.01
125I-IL-1 ra 1.46±0.05 0.39±0.02 0.08±0.01 0.03±0.005
Kidney >25I-IL-1 1.51 ±0.07 0.59±0.04 0.40±0.03 0.24±0.01
125I-IL-1 ra 6.16±0.78 1.19±0.20 0.44±0.02 0.39±0.04
Liver I25I-IL-1 1.05±0.07 0.32±0.01 0.22±0.01 0.13±0.004
125I-IL-1 ra 3.73±0.51 1.06±0.06 0.10±0.01 0.03±0.007
Intestine »«I-IL-l 1.07±0.09 0.20±0.02 0.07±0.004 0.03±0.004
125I-IL-1 ra 2.39±0.26 0.37±0.06 0.11 ±0.04 0.06±0.03
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Fig. 3. The absolute abscess uptake of 125I-IL-1 and 125I-IL-1 ra at 
various time points, expressed as %dose/g. The error bars indi­
cate s.e.m.
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Fig. 4. Abscess-to-(contralateral) muscle ratios of l25I-IL-l and 
125I-IL-1 ra at various time points. The error bars indicate s.e.m.
Table 2. Biodistribution of 125I-IL-1 ra with co-injected unlabelled 
IL-1 (%dose/g, mean values ±s.e.m.)
Organ 4 h p.i. 12 h p.i. 24 h p.i. 48 h p.i.
Blood 1,02±0.06 0 .19±0.02 0.04±0.004 0.01 ±0.004
Abscess 0.83±0.08 0.26±0.09 0.12±0.02 0.06±0.01
Muscle 0.23±0.04 0.04±0.003 0.01 ±0.004 0.01 ±0.004
Thymus 0.72±0.14 0.14±0.03 0.04±0.02 0.01 ±0.004
Lung 1.04±0.08 0.23±0.01 0.08±0.01 0.03±0.004
Spleen 1.18±0.13 0.25±0.04 0.07±0.01 0.02±0.004
Kidney 5.50±0.39 1.16±0.13 0.53±0.04 0.33±0.03
Liver 3.36±0.42 0.41 ±0.05 0.09±0.01 0.04±0.01
Intestine 2.61 ±0.56 0.31 ±0.13 0.05±0.01 0.02±0.004
fore, our results demonstrate that a receptor antagonist 
may not localize in infectious foci while its agonist is 
specifically retained at the site of inflammatory cells.
There may be several possible explanations for the 
difference in abscess uptake of IL-1 and IL-lra. Firstly, 
since human recombinant IL-lra was injected in mice, 
species specificity may play a role. Human IL-lra is 
76% identical to its murine counterpart [10]. The differ­
ences may be responsible for the low abscess uptake of 
,25I-IL-lra. Secondly, internalization of the radiolabelled 
protein after binding to its receptor on inflammatory 
cells may be essential for retention of the protein in the 
infection. Studies have shown that the majority of sur­
face-bound 125I-IL-1 is internalized at 37°C within a few 
hours. It does not undergo degradation for at least 6 h af­
ter internalization [11]. However, in contrast to IL-1, 
surface-bound IL-lra does not undergo receptor-mediat­
ed internalization [5]. Finally, association of IL-lra with 
serum proteins in circulation - as demonstrated by 
HPLC analysis - may make it less available for IL-1 re­
ceptor binding in the infectious focus. This phenomenon 
was not observed for IL-1. Aggregation could be ru ed 
out since most radioactivity was found at 17 kDa after 
4 h incubation in PBS at 37°C.
Our study showed that the lack of biological activity 
of IL-lra does not explain the low retention in the in­
flammatory focus. The biological activity of IL-1, in­
cluding a wide range of inflammatory and immunologi­
cal effects, did not influence the abscess uptake of L- 
lra when unlabelled IL-1 was co-injected with radiola­
belled IL-lra.
IL-lra could only be succesfully labelled by using the 
Bolton-Hunter method. Other radioiodination methods 
significantly reduced the receptor binding capability ol 
IL-lra (data not shown). For comparison, IL-1 was alsc 
labelled according to the Bolton-Hunter method. W( 
prefer to use the iodogen labelling method for radioiodi 
nation of IL-1 because of the higher labelling efficienc; 
[3]. It appeared that the labelling method influenced tin 
clearance of the radiolabelled protein. The Bolton-Hunt 
er method resulted in faster blood clearance of radioiodi 
nated IL-1 than did the iodogen method. Nevertheless 
the retention in the abscess was similarly high, demon 
strating that the binding of radiolabelled IL-1 to inflair 
matory cells already takes place in the initial hours posi 
injection. During the following hours, non-bound IL- 
will be removed from the tissues, while bound IL-1 is n 
tained in the infection.
Discussion
This paper has described a direct comparison of radioio- 
dinated IL-1 and its receptor antagonist in vitro and in 
vivo in an animal model of infection. Despite the highly 
similar in vitro characteristics of the two proteins, the in 
vivo behaviour was different. The retention of IL-lra in 
the abscess was 10 times lower than that of IL-1. There-
Conclusion
IL-lra could have been the ideal alternative to IL-1 
circumvent the toxicity of IL-1 and to use the recept 
binding capacity for infection imaging. However, th 
study showed a significantly lower retention in the inie 
tion of IL-lra compared to IL-1. This may be caused I 
specific molecular properties of IL-lra, such as associ
0.00
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(ion with serum proteins in vivo, indicating that human 
recombinant IL-lra is less advantageous for imaging of 
infection and inflammation. Instead of looking at IL-lra, 
tli development of a technetium-99m labelling method 
with high specific activity using IL-1 seems to be a more 
a| iropriate direction. Theoretically, when at least one
0 Tc atom is incorporated per IL-1 molecule, very low 
a mnts of protein (<10 ng/kg) which are nevertheless 
su ficient for imaging purposes can be injected in pa- 
(i its without causing any side-effects. Our future plans 
w 1 focus on the development of 99mTc labelling of IL-1 
w h sufficiently high specific activity.
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